What is the role of radioimmunotherapy in the treatment of mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Both iodine-131–based tositumomab (Bexxar) [28] and yttrium-90–based ibritumomab tiuxetan (Zevalin) [29] have shown activity as single agents for salvage therapy in persons with MCL. Studies have reported responses with radioimmunotherapy (RIT) in MCL, including some complete responses that lasted more than 1 year. Additional ongoing studies are exploring combinations of RIT with chemotherapy for untreated or relapsed MCL. Strategies including RIT as part of high-dose therapy have shown encouraging results.

The use of RIT as part of a nonmyeloablative allotransplantation conditioning regimen is another promising strategy currently being tested in clinical trials.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!